A respected cancer foundation is collaborating with Stanford University to focus on a subset of cancer patients whose tumors have ROS1 gene fusions. ROS1 is a unique genomic abnormality that’s seen in several cancers including gastric cancer.
Research investigators and clinicians who work in the ROS1 fusion space, as well as pharma partners, are coming together in a collaborative effort to change the state of the science and treatments for ROS1 fusion positive patients. according to the Bonnie J. Addario Lung Cancer Foundation, the sponsoring organization.
Gastric patients as well as others with ROS1 fusions are invited to participate in the effort by filling out the following survey: lungcancerfoundation.org/ROS1